Tag Archives: FDA

Walk again after 24 years on wheel chair using Stem Cells

From wheel chair to walk again

William Orr hasn’t always been in that wheelchair, 24 years ago he survived a tragic accident while riding his bike, leaving him paralyzed from the waist down. Today, he speaks with high hopes, optimism, and an emotional strength he will one day walk again, thanks to a Bonita Springs doctor.

Bill Orr is not quite walking. But he’s getting close. And his progress may be one of the best stories of 2010 for a whole lot of reasons.

The 50-year-old Aurora man has been a quadriplegic for half his life —
Read More…

Replacing Need For Orthopedic Surgery in USA

Stem Cell Research- Already Paying Dividends in Colorado
Dr. Christopher Centeno, a pioneer in stem cell research in Broomfield, Colorado is now treating patients with osteoarthritis, joint pain, knee injuries and non-healing broken bones at his clinic using the patient’s own Adult Stem Cells to repair the damage.
Goodbye Ankle Surgery- Stem Cell Treatment Instead
Hal Kaye, an […]

Medistem Achieves Important ERC Stem Cell Milestone

Medistem Inc. announced today positive safety data from the first 5 patients enrolled in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The clinical trial uses the company’s “Universal Donor” Endometrial Regenerative Cells (ERC) to treat Congestive Heart Failure (CHF).

According to the study design, after 5 patients enter the trial, they must be observed for a two month time period before additional patients are allowed to enter the study. Patient data was analyzed by the study’s independent Data Safety Monitoring Board (DSMB), which concluded that based on lack of adverse effects,
Read More…

The FDA Is Killing Adult Stem Cell Therapy Thus Killing Patients

Drug Companies and FDA Trying to Slow Adult Stem Cell Progress
In a startling new interview on stem cell research and adult stem cells in the near future, Dr. Christopher Centeno warns that Big Pharma and the FDA are teaming to control the use of a person’s own stem cells thus slowing innovation and the […]

Geron explains stop on stem cell study

MENLO PARK, Calif., August 18, 2009 – Geron Corporation announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.

Since filing the IND, Geron has been undertaking studies to enable dose escalation of its spinal cord injury product, and has been investigating application
Read More…